StockWatch
·

FIRST SOLAR, INC. Q2 FY26 Results

FSLRQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue1.1K1.1%3.7%
Total Income1.1K1.1%3.7%
Expenditure605.8113.3%17.6%
PBT459.3829.6%30.4%
Net Profit422.5721.9%23.6%
OPM42.64%9.58pp9.68pp
NPM40.01%6.82pp8.85pp
EPS3.9321.7%23.2%
View full financials

First Solar Announces Q2 2026 Results, Reaffirms Guidance

31 Jul 2026 · 31 Jul, 1:39 am

Summary

First Solar announced its financial results for the second quarter of 2026, reporting net sales of $1.06 billion, a 4% decrease year-over-year, attributed to lower revenue from customer contract terminations. Despite the revenue dip, net income per diluted share saw a significant increase of 23% to $3.92, and Adjusted EBITDA grew to $644 million from $560 million in the prior year. The company reaffirmed its full-year 2026 guidance and highlighted a robust contracted sales backlog of 45.1 GW, demonstrating continued demand for its technology.

Key Highlights

  1. 1

    First Solar reported net sales of $1.06 billion for the second quarter of 2026, a 4% decrease year-over-year.

  2. 2

    Net income per diluted share increased by 23% year-over-year to $3.92.

  3. 3

    Adjusted EBITDA for the second quarter was $644 million, an increase from $560 million in the prior year's second quarter.

  4. 4

    The company maintained a strong contracted sales backlog of 45.1 GW as of June 30, 2026.

  5. 5

    First Solar reaffirmed its full-year 2026 guidance for net sales, gross profit, and Adjusted EBITDA.

Management Comments

M

Mark Widmar

We delivered both record second-quarter and first-half sales volume and improved financial performance relative to the prior year. We also surpassed 100 GW of cumulative module sales globally and ended the quarter with approximately 45.1 GW of contracted backlog extending through 2030, demonstrating continued demand for our differentiated technology platform, domestic manufacturing footprint and delivery certainty.

Informational and educational content only. Not investment advice.